Login / Signup
Didier Meulendijks
ORCID
Publication Activity (10 Years)
Years Active: 2020-2023
Publications (10 Years): 2
Top Topics
Healthcare
Small Molecule
Adverse Drug
Top Venues
Future oncology (London, England)
Clinical pharmacology and therapeutics
</>
This page only lists publications with an associated author ORCID identifier.
Publications
</>
Paul-Michael Agapow
,
Rob Mulla
,
Natasha Markuzon
,
Lone H Ottesen
,
Didier Meulendijks
Systematic review of time to subsequent therapy as a candidate surrogate endpoint in advanced solid tumors.
Future oncology (London, England)
(2023)
Marc Maliepaard
,
Timi Toiviainen
,
Marie Louise De Bruin
,
Didier Meulendijks
Pharmacogenetic-Pharmacokinetic Interactions in Drug Marketing Authorization Applications via the European Medicines Agency Between 2014 and 2017.
Clinical pharmacology and therapeutics
108 (2) (2020)